Evidence-based comp...
 

Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin  

  RSS

Daniel
(@daniel)
New Member Admin
Joined: 4 years ago
Posts: 310
25/10/2018 1:11 pm  

Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049054/

Despite new and exciting research and renewed optimism about future therapy, current statistics of survival from pancreatic cancer remains dismal. Patients seeking alternative or complementary treatments should be warned to avoid the hype and instead look to real science. A variety of relatively safe and inexpensive treatment options that have shown success in preclinical models and/or retrospective studies are currently available. Patients require their physicians to provide therapeutic guidance and assistance in obtaining and administrating these various therapies. Paricalcitol, an analog of vitamin D, has been shown by researchers at the Salk Institute for Biological Studies to break though the protective stroma surrounding tumor cells. Hydroxychloroquine has been shown to inhibit autophagy, a process by which dying cells recycle injured organelles and internal toxins to generate needed energy for survival and reproduction. Intravenous vitamin C creates a toxic accumulation of hydrogen peroxide within cancer cells, hastening their death. Metformin inhibits mitochondrial oxidative metabolism utilized by cancer stem cells. Statins inhibit not only cholesterol but also other factors in the same pathway that affect cancer cell growth, protein synthesis, and cell cycle progression. A novel formulation of curcumin may prevent resistance to chemotherapy and inhibit pancreatic cancer cell proliferation. Aspirin therapy has been shown to prevent pancreatic cancer and may be useful to prevent recurrence. These therapies are all currently available and are reviewed in this paper with emphasis on the most recent laboratory research and clinical studies.


Quote
Jcancom
(@jcancom)
New Member
Joined: 2 years ago
Posts: 108
25/10/2018 6:57 pm  

D, I went back to some of the early 3-BP research and I found this one.  It found that an HSP90 inhibitor (geldanamycin) combined very well with 3-BP. Apparently hypoxic cells often present a large problem for chemo drugs, though for some reason geldanamycin did extremely well in hypoxic pancreatic cancer cell  environments. It is very frustrating that this research was never brought forward. Geldanamycin is considered toxic so this might not have a great deal of clinical translation potential, though it seems worthwhile to mention.   PMID:18347186


ReplyQuote
Share: